Incyte Corp (Incyte) discovers, develops, and commercializes proprietary drugs for the treatment of cancer and hematologic conditions. The company reports its business through a single segment, which focuses on the discovery, development, and commercialization of proprietary therapeutics. Its commercial products include Jakafi, Iclusig, Pemazyre, Monjuvi, Niktimvo and Opzelura.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Incyte's R&D arm focuses on core expertise in medicinal chemistry and biologics, supported by an experienced team across various scientific and therapeutic areas. The company has expanded its competencies beyond small and large molecules to include degraders and bispecific and multispecific antibodies. Incyte has established comprehensive in-house discovery capabilities, including target identification and validation, high-throughput screening, medicinal chemistry, protein sciences and technology, computational and AI-guided drug discovery, structural biology, pharmacology, translational sciences, drug metabolism and pharmacokinetics, bioanalysis, and toxicology assessment. Strategic collaborations with academic institutions, contract research organizations, and biotechnology companies further enhance these capabilities. The company's pipeline focuses on targeted oncology, myeloid diseases, and dermatology, with a strategy to rapidly advance lead candidates into proof-of-concept clinical trials. Incyte's R&D activities are managed by its discovery team, which operates in concert with global technical operations and development groups. These groups have expertise in drug manufacturing, regulatory affairs, trial design, statistics, pharmacovigilance, project management, and medical affairs. The company collaborate to assess clinical compound development opportunities, select optimal indications, and create plans for regulatory advancement, clinical trial management, and patient safety. Incyte has 16 molecular targets, 19 clinical compounds, and 10 approved products in its pipeline. The company has major technology alliances with Novartis, Lilly, and Syndax, among others. In FY2025, the company spent US$2,050.2 million on its R&D, which as a percentage of revenue, stood at 39.9%, and declined 21.4% YoY.